Alzheimer’s disease (AD) is a progressive neurodegenerative disease that impairs cognition and memory. In the United States, the number of Americans, aged 65 and older, living with AD is expected to increase more than double from the year 2020 to 2060. The high prevalence and burden of the disease have led to increasing efforts in finding a potential treatment. Although there is currently no cure for AD, lecanemab has shown evidence of slowing AD progression. This mini-review provides a brief summary on the several clinical trials that led to its Food and Drug Administration approval for mild cognitive impair and dementia in AD, and the potential concerns surrounding the approval of the drug.
Ueda-Martinez et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: